On Monday, Eli Lilly And Co (NYSE:LLY) announced data from a VIVID-1 Phase 3 study that evaluated the safety and efficacy of ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

Eli Lilly and Company (NYSE: LLY) announced data demonstrating more patients with moderately to severely active Crohn's ...

Eli Lilly announced data demonstrating more patients with moderately to severely active Crohn’s disease treated with ...

Shares of drug maker Eli Lilly ($LLY) were little changed at the time of writing despite announcing results from its Phase 3 ...

US pharma major Eli Lilly has released new data demonstrating more patients with moderately to severely active Crohn's ...

Lilly announces positive results from phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease: Indianapolis Tuesday, October 15, 2024, 18:00 Hrs [IST] Eli Lilly a ...

(RTTNews) - Eli Lilly and Company (LLY) Monday announced 1-year histologic data from the Phase 3 VIVID-1 study of mirikizumab in people with Crohn's disease, a type of inflammatory bowel disease.

Eli Lilly LLY announced encouraging data from the phase III VIVID-1 study, which evaluated its IL-23p19 antibody mirikizumab for adult patients with moderate-to-severe Crohn’s disease (“CD”).

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) has unveiled new data indicating that mirikizumab, its investigational treatment for Crohn's disease, achieved a higher rate of histologic ...

Data show more patients treated with mirikizumab achieved histologic response at Week 52 compared to ustekinumab INDIANAPOLIS, Oct. 14, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE ...